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Abstract
Background: Behçet’s Disease (BD) is a chronic auto-inflammatory, multisystem relapsing/remitting disorder of
unknown aetiology. Oro-genital ulceration is a key feature of the disease and has a major impact on the patients’
quality of life. Other clinical manifestations include ocular inflammation, rheumatologic and skin involvement, while
CNS and vascular complications can lead to considerable morbidity. The availability of a valid monitoring tool for
BD activity is crucial in evaluating the impact of the disease on daily life activity. The aims of this study were to
validate a novel tool for monitoring genital ulceration severity in BD and to assess the impact of genital ulcers on
the Genital Health Quality of Life (GHQoL).
Methods: Genital Ulcer Severity Score (GUSS) was developed using six genital ulcer characteristics: number, size,
duration, ulcer-free period, pain and site. A total of 207 BD patients were examined, (137 females: mean age ± SD:
39.83 ± 13.42 and 70 males: mean age ± SD: 39.98 ± 11.95) from the multidisciplinary Behçet’s Centre of Excellence
at Barts Health NHS Trust. GUSS was used in conjunction with Behçet’s Disease Current Activity Form (BDCAF).
Results: The over-all score of GUSS showed a strong correlation with all genital ulcer characteristics, and the
strongest correlation was with the pain domain (r = 0.936; P < 0.0001). Ulcer average size and ulcer pain were the
major predicting factors in GUSS (β = 0.284; β = 0.275) respectively, and P-values were significant. Multivariate
regression analysis indicated that the ulcer pain, size and site are the main ulcer characteristics having an influence
on the GHQoL (R2: 0.600; P < 0.0001).
Conclusions: This study established the practicality of GUSS as a severity monitoring tool for BD genital ulcers and
validated its use in 207 patients. Genital ulcers of BD have a considerable impact on the patients GHQoL.
Keywords: Behçet’s disease, Genital ulcer, Severity, Genital health quality of life
Background
Behçet’s Disease (BD) is a chronic auto-inflammatory,
multisystem, peri-vasculitis disorder [1, 2], first de-
scribed by the Turkish dermatologist Hulusi Behçet in
1937 [3]. BD is characterised by recurrent mucocutane-
ous lesions [4]. Oro-genital ulcers are usually the first
sign and the main classification criteria of BD patients
[5]. Skin lesions, relapsing uveitis, and articular, neuro-
logic, urologic, intestinal and pulmonary manifestations
can cause serious disability and significant impairment
in the quality of life [6]. The aetiology and pathogenesis
of BD is not fully clarified, however, the BD symptoms
are considered to be based on the correlation between
intrinsic factors (genetic) and triggering extrinsic fac-
tors (microbial and/or environmental), hormonal and
immune system dysregulation are implicated in causing
both reversible and irreversible organ damage [7]. BD is
diagnosed based on the clinical criteria as established
by Mason and Barnes (1969), O’Duffy and Goldstein
(1974) [8]. The international study group (ISG1990) cri-
teria were subsequently published to include a positive
Pathergy test as one of BD criteria [9]. The most recent
diagnostic criteria is that of the International Team for
the Revision of the International Criteria for BD
(Davatchi et al. 2014), which used a numerical scoring
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system with a sensitivity of 98.2 % and a specificity of
95.6 % in a 27 country BD cohort [10, 11].
The prevalence of BD is highest in Middle Eastern
countries such as Turkey where it occurs in approxi-
mately 370/100,000 inhabitants and in Iran with a preva-
lence of 80/100,000 [12]. BD also occurs in Central and
far Eastern Asian countries and is said to track the “Old
Silk Road” trading routes [13]. BD is less common in
northern Europe and the USA: with 4.2/100,000 in
Germany; 7.2/100,000 in France; 8.6/100,000 in the
USA; and 0.64/100,000 in the United Kingdom respect-
ively [12]. BD onset usually occurs in mid third to fourth
decade of life with almost equal male to female ratio, al-
though men often have more severe symptoms [14].
BD disease course, severity, and systemic involvement
between patients is variable, and the treatment depends
on gender, age and weight (for calculation of drug dose)
at presentation, therefore, it is challenging to determine
a single management strategy [15]. Colchicine is widely
used in treatment protocols for the mucocutaneous
manifestations of BD and corticosteroid therapies and
immunomodulatory drugs including biologic drugs
will control active disease and remission in cases of
major organ involvement that are unresponsive to
conventional therapy [16].
Genital ulcers caused by BD are the second most com-
mon manifestation of BD [17], occurring in 57 % to 96 %
of patients [18–20]. However, Alekberova et al. [21] found
that the two major diagnostic criteria, namely aphthous
stomatitis and external genital ulcers, were found with the
same frequency. Genital ulcers typically start as a tender
nodule, becoming deep and painful: interfering with sit-
ting, walking and causing dysfunction, and usually healing
slowly with scarring [22]. In females they are typically
found on the labia majora, labia minora, on the vulva,
perineum, or perianal skin. In males ulcers are mostly seen
on the scrotum, less frequently on the shaft of the penis
and occasionally on the tip of the penis [12]. Genital ulcer-
ation in BD is not contagious and cannot be spread
through sexual intercourse; however, bacterial colonisa-
tion of ulcers may be a risk factor for the transmission of
infection to sexual partners. Genital ulcers in BD resemble
oral ulcers in appearance and clinical course [9, 13] and
have been classified into three groups: minor aphthae that
are smaller than 1 cm, major aphthae larger than 1 cm,
and herpetiform aphthae that are multiple, very small
ulcers [23]. The complexity of systemic symptoms and
resistance to conventional treatment of BD patients can
lead to both a temporary and permanent functional
disability while neurological involvement can lead to men-
tal impairment [24, 25]. Previous studies indicate that
mucocutaneous-symptoms may cause deterioration in
personal relationships and daily activity and impact on the
QoL of BD [26, 27].
Mucocutaneous lesions in BD are important in presen-
tation and diagnosis, and are considered hallmarks of
BD [28]. Monitoring approaches include patients’ med-
ical history, physical examination and specific serological
tests are mandatory, however, these methods have limi-
tations in measuring the effect of the disease on organ
function. A scoring system, such as GUSS, would be
extremely useful in measuring BD severity and treatment
efficacy in clinical trials and assessing disease status at a
given time during cross sectional studies and in tracking
the evolution of disease over time by longitudinal
observation.
In this clinical prospective study, we have designed
and validated a tool for measuring genital ulcerations
that will benefit the assessment BD patients’ disease sta-
tus with respect to current and prospective therapies.
This study also adds to the previous data by analysing
the impact of GUSS on daily activity. The four factors
are; siting, walking, passing urine and sexual activity,
that interfere with their GHQoL at the time of genital
ulceration.
Methods
This prospective study is a part of The City Research
Ethical Committee (COREC) approved study “Immune-
regulation at the mucosal barrier” (P/03/122) and was
carried out at Barts Health NHS Trust in full compli-
ance with the Helsinki Declaration [29]. A cohort of 207
out of 263 fully consented BD patients classified accord-
ing to the international study group (ISG) 1990 [30, 31],
gave written consent for oral and genital assessment and
examination. The GUSS forms (Fig. 1) were completed
during the clinical assessment of the patients by the cli-
nicians and senior specialist nurse at Behçet’s Centre of
Excellence at Barts NHS Trust.
The exclusion criteria for the BD cohort were as follows;
patients not fully diagnosed according to the ISG 1990;
pregnant and lactating BD mothers were also excluded.
Genital Ulcer Severity Score (GUSS) form
The GUSS form has been developed as a modification of
the OUSS tool established by Tappuni et al. [32]. Six
OUSS characteristics (number, size, duration, ulcer-free
period, pain and site) were recorded and extended to
include; evidence of scarring, and discharge to evaluate
the severity of the genital ulceration in BD and to assess
their effect on GHQoL at the time when the disease is
active. Other confounding factors were also monitored
such as potentially harmful habits including excessive
use of soap, perfumed hair removal products, tattoos
and metal studs in the genital area. Medications includ-
ing the name, type, frequency and the duration of the
therapy were also recorded for monitoring the efficacy
of the treatment protocols for each patient.
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To complete the GUSS form, the ulcers’ characteristics
were converted into numerical values, in order to assess
the genital ulcers in BD patients for the preceding
4 weeks.
The guidelines for GUSS domains calculation were as
follows:
Average number of ulcers: the score corresponds to
the average number of ulcers per episode. i.e. Score 1 if
there was one ulcer and score 2 if there were two
ulcers etc. The maximum number is 20.
Average size of ulcers: the score is the average of the
ulcer diameter in millimetres. A size diagram was
Fig. 1 The Genital Ulcer Severity Score Form in BD
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provided as circles at the bottom of the GUSS form.
The maximum score is 20 mm. i.e. score 2 for the
ulcer’s size of 2 mm etc. If the patient was uncertain of
the size (between two different size circles) then an
average of the ulcers’ size were recorded.
Duration of ulcers: the score corresponds to the
average duration of the ulcers and was calculated in ½
week units; i.e. Half week (3 days) = 1, one week and
half = 3 etc. The maximum score is 10.
Ulcer-free period: the score corresponds to the time free
of ulcers in a period of 4 weeks; i.e. if the patient was free
from ulcers for 1 week, the score = 3. The maximum
score is 4 when the patient is never free from ulcers.
Pain: The use of the validated pain visual analogue scale
in the GUSS form allows the patients to quantify their
pain during the time of ulceration. The minimum score
is 0 (no pain) and the maximum score is 10 (severe pain).
Ulcer site: this estimates the most frequent sites which
are affected by ulcers in the genital skin/mucosa in
males and females. Score 1 each for the most common
affected sites and score 2 each for the less common
affected sites in genital.
Discharge: an evaluation by the patient answering if there
was a fluid discharge or not at the time of ulceration.
Evidence of scarring: evaluated by the clinician at the
time of assessment.
Genital Health Quality of Life (GHQoL): A scale from
0 (does not interfere with the GHQoL) to 10
(excruciating ulcers interfering with GHQoL) was
included to correlate the GUSS with the patients’
GHQoL at the time of episodes in terms of (walking,
sitting, passing urine and sexual activity).
Behçet’s Disease Current Activity Form (BDCAF)
The BDCAF form [33] is a well-established tool for the
assessment of BD activity in the clinic, which scores the
history of clinical features; fatigue, headache, mouth
ulcer and/or genital ulcer, skin lesions, joint involve-
ment, blood vessel involvement, gastrointestinal and
CNS complications, which present over the four weeks
prior to the day of assessment. The form is completed
by the patient in conjunction with a senior nurse (to
help with any clarification required). The clinicians’ im-
pression of disease activity was then included in the
BDCAF score on scale from 0 to 12.
Behçet’s disease treatment pathway
Treatment decisions varied, depending on the patients’
disease activity and symptoms and were based on the
European League Against Rheumatism (EULAR) guid-
ance for Behçet’s disease [34], and Behçet’s Centre of
Excellence protocol for management of BD. These were
followed to prevent/arrest any irreversible damages.
Validation of GUSS form
The validity is defined as the degree to which a scale
correlates with a theoretic concept [35]. To assess the
validity of the GUSS: 1) we correlated the genital ulcer
domains with the over-all GUSS, 2) The negative impact
of genital ulceration on the patients’ GHQoL, therefore,
the ulcer six characteristics were correlated with BDCAF
and the GHQoL factors.
Statistical analysis
The descriptive analysis was performed for mean and
standard deviation values. The results were analysed by
using the IBM SPSS Statistics software (version 20 for
Windows; IBM Corporation, New York, NY, USA). Inde-
pendent t-test and one-way ANOVA test were done to
compare gender and age range groups with the GHQoL.
The relationship between the variables was assessed by
Pearson coefficient analysis. Multivariate regression analysis
Table 1 Behçet's disease clinical systemic activitya
BD clinical systemic activitya Pt. Number/total %
Mouth 69/207 33.3 %
Genital 54/207 26.1 %
Mouth and Genital 19/207 9.18 %
Eyes 33/207 15.9 %
Skin 45/207 21.7 %
Joints 73/207 35.2 %
CNS 42/207 20.2 %
Active BD 127/207 61.4 %
Inactive BD 70/207 33.8 %
aBD activity on the day of clinical assessment
Table 2 Medications used by our BD cohort
BD medication Pt. Number/total %
No BD medication 24/207 11.6 %
One systemic medicine 51/207 24.6 %
Two systemic medicines 62/207 30 %
More than two systemic medicines 42/207 20.3 %
Medications’ name
Prednisolone 85/207 41 %
Colchicine 82/207 39.6 %
Azathioprine 63/207 30.4 %
Mycophenolate Mofetil (MMF) 20/207 9.6 %
Infliximab 15/207 7.2 %
Humira 12/207 5.7 %
Methotrexate 7/207 3.4 %
Topical steroids oral medicine 121/207 58.5 %
Topical steroids genital medicine 36/207 17.4 %
Topical steroids skin medicine 5/207 2.41 %
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was performed for assessing the influence of the six charac-
teristics of genital ulcers on the GUSS and the GHQoL, as
the outcome measure resembled the normal distribution.
The calculated P value < 0.05 was considered statistically
significant. The correlation between the variables were
ranked as “weak” or no association with values between 0
and 0.29 or (0 and −0.29), “moderate” with values between
0.3 and 0.69 or (−0.3 and −0.69), and “strong” if they were
between 0.7 and 1 or (−0.7 and −1). The R-squared is the
proportion of variance in the dependent variable that is ex-
plained by the additive combination of effects of the inde-
pendent variables, and The ANOVA results indicate that
the regression is significant or not significant. Beta value
(standardised regression coefficients) is a measure of how
strongly each predictor variables influences the dependent
variable. The higher the beta value the greater the impact
of the predictor variables on the dependent variable.
Results
The genital ulcer severity of 137 females (mean age ±
SD: 39.83 ± 13.42) and 70 males (mean age ± SD: 39.98 ±
11.95) was recorded. The frequency of genital ulceration
in BD patients per a year was (mean of frequency ± SD:
7.13 ± 6.83), from the Multidisciplinary Behçet’s Centre
of Excellence at Barts Health NHS Trust were moni-
tored and calculated.
42%
25%
13%
8%
8%
4%
Genital ulcer sites in males
Scrotum
Penis shaft
Penis
Perineal
Perianal
Groin
31%
26%
18%
9%
2%
8%
4%
2%
Genital ulcer sites in females
Labia minora
Labia majora
Vulva
Intravaginal
 Cervical
Perineal
Perianal
Groin
Female Male
a)
c)
b)
Fig. 2 Genital ulcers in males and females. a Genital ulcer distribution in males, b Genital ulcer distribution in females c GHQoL and gender
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Symptoms and Behçet’s disease activity
On the day of clinical assessment, all of BD patients
were classified according to their BD activity, 61.4 %
patients (n = 127) were active, whereas 33.8 % were
inactive (n = 70). From the active disease group, a
total of 69/207 (33.3 %) had oral ulceration, while
(54/207, 26.1 %) had genital ulcers and most of the
genital ulcers were herpetiform and minor in size.
Age Range in years
a)
b)
Age range in years
Fig. 3 GUSS and Genital Health Quality of Life with BD patients’ age. a GUSS and the age b GHQoL and age range
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Almost 26 % of patients had a fluid discharge during
the ulceration period, and 18 % had scarring in their
genital area. In term of harmful habits, 2 patients had
a tattoo, 1 patient had metal studs and 5 patients was
used excessive soap to clean the genital area. Only
19/207 (9.18 %) patients had oral and genital ulcer-
ation at the same time. 21.7 % (45/207) of patients
presented with skin manifestations such as erythema
nodosum, pseudofolliculitis and papulopustular lesions,
while joint and central nervous system manifestations,
commonly presented as headache, were 73/207 (35.2 %)
and 42/207 (20.2 %) respectively. Ocular manifestations
occurred in 33/207 (15.9 %) patients (Table 1).
Treatment modalities
About 20.3 % (42/207) were treated by multiple (more than
2) immunomodulatory medicines, 30 % (62/207) patients
received two immunomodulatory medications. 51 received
one immunomodulatory medication and 24 patients out of
207 required no medication at the time of presentation.
The most common immunomodulatory medications
were as follows: Prednisolone 41 % (85/207) used pre-
dominantly during relapsed episodes; Colchicine,
39.6 % (82/207); Azathioprine, 30.4 % (63/207); Myco-
phenolate Mofetil (MMF) 9.6 % (20/207) and Metho-
trexate, 3.4 % (7/207). Infliximab was prescribed to
7.2 % (15/207); Humira 5.7 %. Topical corticosteroids
for the oral ulcers were used in 58.5 % (121/207) of
patients who used either Betamethasone mouthwash or
Triple Therapy Mouthwash (1 tablet Betamethasone
500 mcg + 1 tablet Doxycycline 100 mg + 1 ml Nystatin
100.000 unit/ml dissolved in 10 ml of water). The pa-
tients are required to keep this solution in their mouth
for 3 min and no food is to be taken for 1 h after use.
These were prescribed for the patients with high OUSS
score for use up to 4 times a day. 17.4 % (36/207) of
patients used topical steroids for genital ulcers. How-
ever, only 5 patients were using the topical steroid
medication for their skin manifestations (Table 2).
The site of genital ulceration and its effect on the GHQoL
The genital ulcers in males were most common in the scro-
tum (42 %, n = 10) followed by the penis shaft (25 %, n = 6)
and the tip of the penis (13 %, n = 3). Ulcers in perianal and
perineal area in males occurred in 8 %, (n = 2) each. In
females the genital ulcers were most frequently recorded in
Table 3 Correlation of GUSS with ulcer characteristics
Correlations
GUSS Ulcer Average
Number
Ulcer Average Size
(mm)
Ulcer Duration
(weeks)
Ulcer Free-Period
(weeks)
Ulcer
Pain
Ulcer
Site
Ulcer Average
Number
Pearson
Correlation
.836 1.000
Sig. (1-tailed) .000*
Ulcer Average Size
(mm)
Pearson
Correlation
.868 .572 1.000
Sig. (1-tailed) .000* .000*
Ulcer Duration
(weeks)
Pearson
Correlation
.873 .712 .662 1.000
Sig. (1-tailed) .000* .000* .000*
Ulcer Free-Period
(weeks)
Pearson
Correlation
.855 .646 .679 .830 1.000
Sig. (1-tailed) .000* .000* .000* .000*
Ulcer Pain Pearson
Correlation
.936 .767 .788 .746 .747 1.000
Sig. (1-tailed) .000* .000* .000* .000* .000*
Ulcer Site Pearson
Correlation
.861 .809 .657 .721 .742 .775 1.000
Sig. (1-tailed) .000* .000* .000* .000* .000* .000*
Significant values are indicated in bold
*P-value < 0.0001 (SPSS)
Table 4 Model summary of GUSS with ulcer characteristics
GUSS
Model Summary R .999a
R Square .998
Sig. (ANOVA) .000*
aPredictors: (Constant), Ulcer Site, Ulcer Average Size (mm), Ulcer Duration
(weeks), Ulcer Average Number, Ulcer Free-Period (weeks), Ulcer Pain
Significant values are indicated in bold
*P- value < 0.0001 (SPSS)
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the labia minora (31 %, n = 29), followed by the labia majora
at (26 %, n = 24). Vulvar ulcers occurred in 18 % of patients
(n = 17) while only 9 % presented with intravaginal ulcers.
Perineal and perianal ulcers were recorded in 8 % and 4 %
respectively, while ulcers in the cervical and groin area were
rare (Fig. 2a, b). Statistically, the result illustrates that male
and female groups are not equal in their GHQoL at the
time of the genital ulceration (p = 0.027). Women had
worse GHQoL than men. However, due to the unequal
number of male and female participants, this finding can-
not be substantiated in this study (Fig. 2c).
The effect of age on GUSS and GHQoL
Genital ulcers were widely distributed with a high severity
score in patients between age ranges (18–30) and (31–43),
within these age ranges males were higher in their GUSS
than females (Fig. 3a), this was consistent with the BD
literature [36, 37]. GUSS mean declined in the higher age
range (44–60) in both genders with no significant differ-
ence between males and females. Interestingly high sever-
ity in GUSS was seen in women over 60 years of age (but
not men). However, there is no difference in the GHQoL
status between our male and female cohorts in all age
ranges (P = 0.345) was shown in (Fig. 3b).
Assessment of GUSS form
The correlation coefficient between genital ulcer charac-
teristics and over-all GUSS showed a strong positive
correlation and P values were significant with all ulcer
domains (Table 3).
The strength of the correlation and the influence of
the variables on GUSS are explained by (R2), and in this
case the value was 0.998, this suggests that our model
(which includes the six ulcer characteristics) explains
99.8 % of the over-all GUSS, and the regression analysis
of GUSS with the six ulcer characteristics is statistically
significant (P < 0.0001).
Beta value results showed that average ulcer size and
then ulcer pain were the major predictive factors in
GUSS (Tables 4 and 5).
The effect of genital ulcer characteristics on the BDCAF
and GHQoL
The correlation between genital ulcer domains and the
total of GHQoL factors; sitting, walking, passing urine,
and sexual activity, using the Pearson coefficient, dem-
onstrated a positive moderate correlation with the pain
domain (r: 0.660; P < 0.0001), with ulcer average size (r:
0.447; P < 0.0001), and ulcer site (r: 0.383; P = 0.003).
Table 6 Correlation of GHQoL factors, BDCAF with ulcer characteristics
Correlations
Sitting Walking Passing Urine Sexual Activity GHQoL BDCAF
Ulcer Avenge Number Pearson Correlation .276 .120 .331 .123 252 .363
Sig. (1-tailed) .024* 198 .008* .192 .035* .004*
Ulcer Average Size (mm) Pearson Correlation .367 .456 .419 .236 .447 .107
Sig. (I-tailed) .004* .000* .001* .046* .000* .225
Ulcer Duration (weeks) Pearson Correlation -.024 .119 -.021 -.265 -.113 .375
Sig. (1-tailed) .434 .201 .440 .029* .203 .003*
Ulcer Free-Period (weeks) Pearson Correlation .247 .139 .152 .145 .200 .250
Sig. (1-tailed) .039* .163 .141 .153 .078 .037*
Ulcer Pain Pearson Correlation .640 .654 .494 .445 .660 .189
Sig. (1-tailed) .000* .000* .000* .000* .000* .089
Ulcer Site Pearson Correlation .376 .419 .320 .213 .383 .218
Sig. (1-tailed) .003* .001* .001* .065 .003* .060
Significant values are indicated in bold
*P- value <0.05 (SPSS)
Table 5 Multivariate regression analysis of ulcer characteristics
with GUSS in BD
Coefficients*
Standardized Coefficients Sig.
Beta
GUSS
Ulcer Average Number .172 .ooo*
Ulcer Average Size (mm) .284 .ooo*
Ulcer Duration (weeks) .193 .ooo*
Ulcer Free-Period (weeks) .111 .ooo*
Ulcer Pain .275 .ooo*
Ulcer Site .100 .ooo*
aDependent variable: Genital Ulcer Severity Score (GUSS)
Significant values are indicated in bold
*P- value < 0.0001 (SPSS)
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The relationship between genital ulcer domains and
BDCAF showed a positive moderate correlation; with
ulcer duration (r: 0.375; P = 0.003), then with ulcer
average number (r: 0.368; P = 0.004) and have positive
weak correlations with the rest of the ulcer characteris-
tics (Table 6).
The multivariate linear regression analysis (Tables 7
and 8), indicated that ulcer characteristics had an influ-
ence on the total of GHQoL (R2: 0.600; P < 0.0001). The
beta values indicate that most of the contributions to
difficulties in sexual activity, walking and sitting were
due to ulcer pain and duration of ulceration, respect-
ively. Ulcer pain was the only factor making a statistical
significant contribution to passing urine.
Discussion
The present study is the first to use GUSS to assess genital
ulcer severity, monitor disease progression and evaluate
the impact of genital ulceration on Genital Health Quality
of Life (GHQoL) in BD.
QoL is a multidimensional measurement relating to
all areas of human behaviour, which has been difficult
to define and to measure because cultural, ethnic, reli-
gious and personal values influence the way that an
individual responds to changes in QoL. Health Quality
of Life (HQoL) attempts to measure how disease af-
fects the quality of life. [38].
BD is a chronic inflammatory multisystem disease with
periods of exacerbation and remission that negatively
impacts on the patients’ QoL, both due to disease itself
or the impact of its symptoms [39].
Our results demonstrate that genital ulcers are common
in females and can occur on the labia, vulva and intravagin-
ally. They present most commonly on the labia minora
followed by labia majora. Genital ulcers are less common in
males and are found most frequently on the scrotum. The
frequent occurrence of genital ulcers in adults between 20
to 40 years may be related to a combination of environ-
mental and hormonal factors [5]. Most of the genital ul-
cers in females were herpetiform in morphology, although
minor and major aphthous ulcers also occur. The over-all
GUSS score being higher in patients with major and her-
petiform ulcers. Our results contribute to previous studies
which indicate that BD severity may lessen as the age of
the patient increases [40, 41]. GHQoL in females was
worse when compared to the male group. This may be the
result of the complexity of the anatomical structures and
thin mucocutaneous tissue in women compared to men.
The multivariate regression analysis demonstrates a
strong positive correlation between genital ulcer char-
acteristics and the over-all GUSS as well as indicating
that the ulcer average size and ulcer pain were major
predictive factors on over-all GUSS.
The pain score significantly correlated with the average
ulcer size particularly in patients with the herpetiform
Table 8 Multivariate regression analysis of ulcer characteristics with GHQoL factors in BD
Coefficientsa
Standardized
Coefficients
Sig. Standardized
Coefficients
Sig. Standardized
Coefficients
Sig. Standardized
Coefficients
Sig.
Beta Beta Beta Beta
Sitting Walking Passing urine Sexual activity
Ulcer Average Number .105 .405 −.121 .287 .248 .087 .041 .773
Ulcer Average Size (mm) .077 .514 .180 .092 .231 .086 −.007 .960
Ulcer Duration (weeks) −.226 .047* −.275 .008* −.161 .204 −.434 .001*
Ulcer Free-Period (weeks) .160 .154 .093 .355 .069 .583 .160 .211
Ulcer Pain .571 .000* .554 .000* .368 .010* .485 .001*
Ulcer Site .152 .238 .316 .008* .045 .757 .088 .548
aDependent Variables: Sitting, Walking, Passing urine and Sexual activity
Significant values are indicated in bold
*P- value < 0.05 (SPSS)
Table 7 Model summary of GHQoL factors and BDCAF with ulcer characteristics
Sitting Walking Passing Urine Sexual Activity GHQoL BDCAF
Model Summary R .724a .783a .624a .615a .775a .504a
R Square .524 .614 .389 .378 .600 .254
Sig. (ANOVA) .000* .000* .001* .001* .000* .033*
aPredictors: (Constant). Ulcer Site. Ulcer Average Size (mm). Ulcer Duration (weeks). Ulcer Average Number. Ulcer Free-Period (weeks). Ulcer Pain
Significant values are indicated in bold
*P- value < 0.05 (SPSS)
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ulceration. This is an important observation as these ul-
cers are frequently missed on examination by clinicians,
leaving patients unable to carry out basic activities such as
sitting, walking, passing urine and sexual intercourse dur-
ing periods of genital ulceration.
Not surprisingly, the correlation between genital ulcer
characteristics and BDCAF was moderate since not all
patients had active systemic disease and genital ulcers con-
comitantly. A finding is supported by previous clinical ob-
servation and the BD epidemiology literature.
In patients with active genital ulcers, the pain, size and
site are the main ulcer characteristics which correlated
with GHQoL [see Additional file 1].
Sexual activity was one of the major factors affecting
the GHQoL of BD patients which may be linked to 1)
constant pain before and after sexual intercourse, 2) the
expectation of developing ulcers subsequent to sexual
intercourse and 3) the sexual partner may have a large
psychological component.
Psychological support is needed in patients with geni-
tal ulceration in BD. The Behçet’s Centre of Excellence
at Barts NHS Trust provides such support.
However, to date there is little information in the litera-
ture regarding the negative impact of BD on the quality of
patients’ sexual life [42]. This suggests an unmet need to
evaluate the impact of genital ulceration on the quality of
life of BD patients, which might provide insights into the re-
quirements of the patients and lead to a step change in the
treatment and support offered for this very sensitive area of
health care and highlights the need and value of a multidis-
ciplinary health team to provide appropriate medical and
psychological care for patients with chronic diseases.
Conclusion
The initial estimation of GUSS validity suggested that
this instrument is a practicable and valid tool for asses-
sing disease activity, disease progression and GHQoL.
Further effectiveness of this scoring system will be-
come more apparent over the next few years as the use
of GUSS has now become an integral part of our routine
patient clinical practice.
Additional file
Additional file 1: GUSS, BDCAF and GHQoL differences based on
patients’ gender (Graph 1) and age range (Graph 2). Sexual activity in
both genders was the highest factor of GHQoL negatively affected by
GUSS. BDCAF was very similar in males and females. GUSS and BDCAF
declined with age. GHQoL became worse with age. However, in a group
of patients’ age over 60, the GHQoL improved and was reflected in a
decrease in GUSS score. (PDF 85 kb)
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